SCHEMBL4637635

SCHEMBL4637635

OCCC#Cc1cccc(F)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
CES2 O00748 2/20 0.34
CES1 P23141 2/20 0.34
BCHE P06276 1/20 0.34
MAPK14 Q16539 8/20 0.34
MME P08473 2/20 0.34
ECE1 P42892 2/20 0.34
HCAR2 Q8TDS4 1/20 0.34
ASIC3 Q9UHC3 1/20 0.33
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
TRPV3 Q8NET8 1/20 0.32
MAP4K4 O95819 1/20 0.31
MAPK11 Q15759 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2953233 0.85 KDM4E (0.47) KDM4EALDH1A1CYP1A2CYP3A4MAPT
SCHEMBL15022608 0.74 KDM4E (0.57) KDM4EALDH1A1CYP1A2CYP3A4MAPT
SCHEMBL25304435 0.73 KDM4E (0.47) KDM4EALDH1A1CYP1A2CYP3A4MAPT
SCHEMBL20234380 0.71 MEP1B (0.35) KDM4EALDH1A1CYP1A2CYP3A4MAPT
SCHEMBL11554454 0.70 ALDH1A1 (0.44) ALDH1A1MAPTMAPK14ASIC3ATM
SCHEMBL21795687 0.70 CES2 (0.35) CYP1A2CES2CES1BCHE
SCHEMBL23320931 0.69 KDM4E (0.44) KDM4EALDH1A1CYP1A2CYP3A4MAPT
SCHEMBL23908785 0.69 CYP3A4 (0.77) KDM4EALDH1A1CYP1A2CYP3A4MAPT
SCHEMBL19302890 0.69 ALDH1A1 (0.47) KDM4EALDH1A1CYP1A2CYP3A4MAPT
SCHEMBL18917798 0.69 ALDH1A1 (0.47) KDM4EALDH1A1CYP1A2CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306045-A1 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors CAMUS LAURE 2008-12-11 US disclosed
US-20080306045-A1 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors CAMUS LAURE 2008-12-11 US disclosed
EP-1951712-A2 CHEMICAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-08-06 EP disclosed
WO-2007059952-A2 1-BENZAZEPINE-3-SULFONYLAMINO-2-PYRRLORIDONES AS FACTOR XA INHIBITORS GLAXO GROUP LIMITED (GB) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306045-A1 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors TFPI, TPSAB1, TFPI2 KDM4E 1310/4885ALDH1A1 308/4885CYP1A2 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.